
## Esteban SÃ;ez-GonzÃ;lez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6722411/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Oxidative Stress in the Pathogenesis of Crohn's Disease and the Interconnection with Immunological Response, Microbiota, External Environmental Factors, and Epigenetics. Antioxidants, 2021, 10, 64.	5.1	41
2	Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease. Digestive Diseases, 2019, 37, 108-115.	1.9	32
3	Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients. Nutrients, 2019, 11, 1059.	4.1	30
4	A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence. Inflammatory Bowel Diseases, 2019, 25, 1681-1691.	1.9	28
5	Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. Inflammatory Bowel Diseases, 2017, 23, 1454-1460.	1.9	25
6	A concise review of opioid-induced esophageal dysfunction: is this a new clinical entity?. Ecological Management and Restoration, 2018, 31, .	0.4	24
7	Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn's Disease. Clinical and Translational Gastroenterology, 2019, 10, e00083.	2.5	22
8	Impact of hepatitis C virus ( <scp>HCV</scp> ) antiviral treatment on the need for liver transplantation ( <scp>LT</scp> ). Liver International, 2018, 38, 1022-1027.	3.9	20
9	The combination of granulocyteâ€monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?. Journal of Clinical Apheresis, 2019, 34, 680-685.	1.3	14
10	Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2017, 62, 1417-1425.	2.3	12
11	Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease. Nutrients, 2019, 11, 1062.	4.1	8
12	Plasma Oncostatin M, TNF-α, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop. Digestive Diseases, 2021, 39, 1-9.	1.9	8
13	Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications. Clinical and Translational Gastroenterology, 2021, 12, e00416.	2.5	7
14	Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-1± drug failure. Digestive and Liver Disease, 2018, 50, 415-417.	0.9	6
15	Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment. Nutrients, 2021, 13, 1770.	4.1	6
16	Epigenetics of Inflammatory Bowel Disease: Unraveling Pathogenic Events. Crohn's & Colitis 360, 2019, 1, .	1.1	5
17	Different Genetic Expression Profiles of Oxidative Stress and Apoptosis-Related Genes in Crohn's Disease. Digestion, 2019, 100, 27-36.	2.3	3
18	Adsorptive granulocyte/monocyte apheresis use in severe ulcerative colitis and determination of changes in plasma cytokines. Journal of Clinical Apheresis, 2018, 33, 99-103	1.3	2

#	Article	IF	CITATIONS
19	Tu1948 α-Defensins(αDef) 1-3 Are Specific Plasmatic Markers for Crohn's Disease (CD) at Diagnosis and Tissue α-Def 5 Methylation Is a Pathogenic Mechanism for αDef-5 Down Regulation in CD. Gastroenterology, 2016, 150, S987.	1.3	ο
20	Opioid-induced functional esophagogastric junction obstruction. GastroenterologÃa Y HepatologÃa (English Edition), 2017, 40, 296-298.	0.1	0